Pfizer and biontech announce publication of results from landmark phase 3 trial of bnt162b2 covid-19 vaccine candidate in the new england journal of medicine

New york and mainz, germany, december 10, 2020 (globe newswire) — pfizer inc. (nyse: pfe) and biontech se (nasdaq: bntx) today announced that the new england journal of medicine  has published safety and final efficacy results from the pivotal phase 3 trial of bnt162b2, their mrna-based covid-19 vaccine candidate. in the trial of 43,448 participants, who were 16 years and older, 21,720 of whom received bnt162b2 and 21,728 placebo, the two-dose regimen of 30 mg bnt162b2, which was given 21 days apart, was well-tolerated and demonstrated vaccine efficacy of 95% against covid-19.
BNTX Ratings Summary
BNTX Quant Ranking